Top Markets
#1 Black Phoenix Black Phoenix +195.60%
#2 Islamic Coin Islamic Coin +158.06%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +28.16%
#5 Acurast Acurast +25.86%
#6 Cryptopia Cryptopia +21.79%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +17.72%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +13.33%
#10 wojak wojak +12.65%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
FluoroPharma Medical, Inc. FluoroPharma Medical, Inc.

FluoroPharma Medical, Inc.

FPMI
Rangering i aksjer #41957
FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the... FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of advanced molecular imaging agents. Initially, its efforts are concentrated on cardiovascular applications within the United States market. The company's pipeline features two notable product candidates: BFPET: An imaging agent designed for stress-testing patients with suspected or confirmed coronary artery disease (CAD), which has successfully completed its Phase I clinical trial. CardioPET: Another molecular imaging agent, currently undergoing a Phase IIa clinical trial. This compound aims to evaluate myocardial blood flow and metabolism in individuals afflicted with CAD. FluoroPharma Medical has established key collaborations, including licensing agreements with Massachusetts General Hospital and Sinotau USA. Furthermore, the company holds clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. Established in 2003, FluoroPharma Medical, Inc. is headquartered in Montclair, New Jersey.
Aksjekurs
$0.0002
Sist synkronisert: 2026-08-11
Markedsverdi
$6.85K
Endring (1 dag)
0.00%
Endring (1 år)
100.00%
Land
US
Handel FluoroPharma Medical, Inc. (FPMI)

Kategori

Healthcare
P/E-forhold for FluoroPharma Medical, Inc. (FPMI)
P/E-forhold per 2026 TTM: 0
Ifølge FluoroPharma Medical, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for FluoroPharma Medical, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.